Clinical trial · Interventional
GROW (Glioma Specialists Reaching Out With Support) Support
GROW Support (Glioma Specialists Reaching Out With Support): Assessment of a Comprehensive Support Program for Low Grade Glioma Patients Post-treatment
NCT05233215CI-TRIAL-00063031withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Funding
Summary
Brief summary (as posted)
This research study is being done to test a participant and caregiver-driven model of follow-up survivorship care,GROW Support (Glioma Specialists Reaching Out With Support), for post-treatment, low grade glioma patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Care Giving Burden | — | UNRESOLVED | — |
| Low-grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
| Survivorship | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GROW (Glioma Specialists Reaching Out With Support) Support Program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GROW Support Program
- description
- Patient participants will fill out questionnaires about emotional and physical health with responses used to develop an individualized survivorship plan conducted through 1x monthly virtual or in-clinic check-ins as well as GROW support meetings as needed for 6 months. Caregiver participants will fill out questionnaires used to develop patient individualized survivorship plan and participate in 1x monthly check-in meetings with patients or separately for 6 months.
- interventionNames
- Behavioral: GROW (Glioma Specialists Reaching Out With Support) Support Program
Primary outcomes (1)
- measure
- Retention Rate
- timeFrame
- 6 months
- description
- Primary outcome is feasibility as defined by 60% of the eligible participants and their caregivers being recruited into the study and completing the initial assessment and associated survivorship plan
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient inclusion criteria include: * Must be at least 18 years of age; * Diagnosed with low grade glioma (WHO grade 1 or 2) * Completed active treatment within the last 2 years and are undergoing surveillance follow-up * Must have at least one caregiver willing to participate as indicated below * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and are able to understand and willing to sign an electronic informed consent document. * Confirms willingness to undergo initial and follow-up questionnaire battery. * Caregiver inclusion criteria include: * Must be at least 18 years of age * Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and able to understand and willing to sign an electronic informed consent document * Consider themselves personally involved in the patient's care and decisions about the care they receive. Exclusion Criteria: * Bipolar disorder, * Psychotic disorders and * Confusion or altered mental state that would prohibit understanding and giving of informed consent. However, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.
References
Publications (0)
Data not yet available
No reference posted for this study.